Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of Adipose-Derived Stem Cell Stromal Vascular Fraction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02590042
Recruitment Status : Not yet recruiting
First Posted : October 28, 2015
Last Update Posted : July 19, 2017
Sponsor:
Information provided by (Responsible Party):
AdiSave Inc.

Brief Summary:
A single-arm, open-labeled, single-center, descriptive and exploratory safety trial using ADSC-SVF-002. ADSC-SVF-002 is an autologous adipose derived stem cell (ADSC)-containing stromal vascular fraction (SVF) obtained from subcutaneous fat harvested by liposuction from a patient. As a cellular therapy product, ADSC-SVF-002 (fresh or cryopreserved) will be administered subcutaneously via injection, with or without unprocessed autologous fat (fresh or cryopreserved), into soft tissue defects and abnormally healing wounds. The primary objective of the trial is to demonstrate the safety of ADSC-SVF-002 in a population of subjects with soft tissue defects or abnormal wound healing who are still symptomatic despite being managed by conventional therapies.

Condition or disease Intervention/treatment Phase
Abnormally Healing Wounds Scars Soft Tissue Defects Biological: ADSC-SVF-002 Phase 1

Detailed Description:

Protocol Number: SJS-CT-001 Phase: Pilot study Methodology: Open label, single-arm Study Duration: Six months after accrual and treatment of the last patient Study Center(s): Single-center Objectives: To demonstrate the safety of subcutaneous administration of autologous ADSC-SVF-002 in a population of subjects with soft tissue defects or abnormal wound healing who are still symptomatic despite being managed by conventional therapies.

Number of Subjects: 10 Diagnosis and Main Inclusion Criteria: Subject has soft tissue deficiencies, soft tissue post traumatic malformations, scars, and/or abnormal wound healing.

Study Product, Dose, Route, Regimen: ADSC-SVF-002. 1.0x106 cells/mL defect (when administered without fat) to 1.2x106 cells/mL defect (when administered with fat). Subcutaneous injection.

Duration of administration: Administration of the product takes approximately 30 minutes. Administered once.

Reference therapy: N/A

Statistical Methodology: Safety outcomes will be reported with descriptive statistics. Secondary (efficacy) outcomes will be assessed relative to baseline (screening) as follows:

  • For outcomes assessed at multiple follow-up visits, one-way ANOVAs followed by the Tukey's test will be conducted
  • For outcomes assessed at one follow-up visit, a Student's t-test will be conducted.

Data will be reported as mean ± SD and p<0.05 will be considered significant.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Open-labeled, Single-arm, Single-centred Study to Test the Safety of ADSC-SVF-002 in Subjects With Soft Tissue Defects or Abnormal Wound Healing
Estimated Study Start Date : October 2017
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : January 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ADSC-SVF-002
Cells will be administered at 1x10^6 cells/mL of defect. If administered with fat, the cells will be administered at 1.2x10^6 cells/mL of defect.
Biological: ADSC-SVF-002

ADSC-SVF with the following identity:

Less than or equal to 10% each CD34 and CD45 positive cells At least 70% each CD90, CD73 and CD105 positive cells Viability of at least 85% Mean Florescence Intensity of less than or equal to 100 C12FDG 0-5-2.5x10^6 cells/g of liposuctioned (hydrated fat)

Other Name: ADSC-SVF manufactured by AdiSave




Primary Outcome Measures :
  1. Continuous monitoring of safety via laboratory tests and physical examinations [ Time Frame: Screening, 48 hours after procedure, and at post-treatment months 1, 2 and 6 ]
    Continuous monitoring of safety as requested by Health Canada


Secondary Outcome Measures :
  1. Physician satisfaction with wound cosmesis, assessed using the Hollander Wound Evaluation Scale [ Time Frame: Screening, 48 hours after procedure, and at post-treatment day 10 and months 1-6 ]
  2. Patient satisfaction with wound cosmesis, assessed using the 100 mm vertical line visual analogue scale [ Time Frame: Screening, 48 hours after procedure, and at post-treatment day 10 and months 1-6 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject has soft tissue deficiencies, soft tissue post traumatic malformations, scars, and/or abnormal wound healing.
  2. Subject is an adult male or non-pregnant female between the ages of 18 to 80 years.
  3. Subject is able to undergo a liposuction procedure in the opinion of the investigator or per facility guidelines.
  4. Subject is able to read, understand and sign a written Informed Consent to participate in the study.
  5. Subject is willing and able to comply with the study protocol, including requirements for taking and abstaining from medications.

Exclusion Criteria:

  1. The subject is a woman of child-bearing potential (not surgically sterile or post-menopausal for at least 1 year as documented in medical history), but is not using a highly effective method of contraception [oral, injected or implanted hormonal methods of contraception; intrauterine device (IUD) or intrauterine system (IUS); condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; or male sterilization (vasectomy)].
  2. Subject has a history of cancer and/or any known conditions/diseases prone to malignancy.
  3. Subject has significant cardiac, renal, or hepatic failure or any other disease that may interfere with the ability to interpret the results of the study.
  4. Subject has an infection, cellulitis, or osteomyelitis diagnosed by MRI and microbiologic culture results.
  5. Subject has an autoimmune disorder.
  6. Subject has a connective, metabolic or atrophic skin disease.
  7. Subject is under chronic anticoagulant therapy.
  8. Subject has a Body Mass Index (BMI) >30.
  9. Subject is positive for HBs antigen, HCV antibody, or HIV antibody.
  10. Subject has received other investigational drug/drugs or unapproved medication within 3 months before registration in this study.
  11. Subject has a history of hematopoietic stem cell transplantation or radio immunotherapy.
  12. Subject has a recent and significant weight loss, the cause of which has not been determined.
  13. Subject has a history of hereditary linked malignancy in a first-degree relative (parent, child, sibling).
  14. Subject is participating in another clinical trial within 6 weeks prior to registration in this study.
  15. Subject has a psychiatric disorder that in the judgment of the investigator could interfere with provision of informed consent, completion of tests, therapy, or follow-up.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02590042


Contacts
Layout table for location contacts
Contact: Keren Leibson, PhD 416 785-7536 info@adisave.com

Locations
Layout table for location information
Canada, Ontario
Forest Hill Institute of Aesthetic Plastic Surgery Recruiting
Toronto, Ontario, Canada, M6C2E3
Contact: Sarah HM Wong, MD    416-289-3200    drsarahwong@gmail.com   
Sponsors and Collaborators
AdiSave Inc.
Investigators
Layout table for investigator information
Principal Investigator: Sarah HM Wong, MD Forest Hill Institute of Aesthetic Plastic Surgery

Additional Information:
Layout table for additonal information
Responsible Party: AdiSave Inc.
ClinicalTrials.gov Identifier: NCT02590042     History of Changes
Other Study ID Numbers: SJS-CT-001
First Posted: October 28, 2015    Key Record Dates
Last Update Posted: July 19, 2017
Last Verified: July 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No